Bile acid research: Basis for new therapeutic concepts
UDCA and norUDCA: two bile acids with a future, not just in hepatology
Symposium 211, Dublin (Ireland), July 2018
Dublin. The interest was enormous: The XXV Bile Acid Meeting of the Falk Foundation e.V. in Dublin was attended by 520 scientists from about 40 countries – more than ever before. This underlines the increasing importance of bile acid research, not only for basic researchers, but also for clinical research. A whole series of bile acids, bile acid analogs, FXR and TGR5 agonists and antagonists are in clinical development, with the potential to influence hepatological and gastrointestinal diseases favorably. There are also promising new findings for the two bile acids UDCA and norUDCA.
More...
Inflammatory bowel diseases
A change in perspective is pending with regard to diagnostics and therapy
Symposium 210, Lisbon (Portugal), April 2018
Lisbon. “Big data” is also currently making its arrival with regard to inflammatory bowel diseases (IBD). For instance, there is an outright flood of data regarding factors which determine pathophysiology – from genome via the exposome and immunome to microbiome.
More...
Liver-Bowel-Microbiome Interactions
On the road to personalized nutritional therapy
Workshop, Hamburg (Germany), January 2018
Hamburg. Diseases of liver and bowel are more closely connected than it has long been supposed. The connector is apparently the microbiome, although the interactions are complex and also include reactions of the immune system and a genetic susceptibility.
More...
A phase of change in IBD – with regard to understanding the disease and therapeutic options
Symposium 209, Berlin (Germany), October 2017
More...
Eosinophilic esophagitis: identify, treat specifically and alleviate sufferingSymposium 208, Berlin (Germany), October 2017
More...
